TRANSVAC2, an European Vaccine Research and Development Infrastructure, supports innovation and accelerates vaccine development by offering high-quality technical services across the R&D pipeline to academic and non-academic research groups, including SMEs.
TRANSVAC services cover all aspects of vaccine development, for:
- Any disease
- Prophylactic and therapeutic vaccines
- Human and veterinary vaccines
- Free of charge (with few exceptions)!
- Researchers developing vaccine candidates against COVID19 are encouraged to apply
Please note that researchers developing vaccine candidates against COVID19 can also benefit from TRANSVAC2 services.
Important date: Apply until April 15th, 2020.
For more information PDF Open Call TransVac2, and for specific inquiries on the details of each service please contact directly service providers. Check all available opportunities at www.transvac.org.